Violeta M Madrigal-Perez, Alejandro García-Rivera, Alejandrina Rodriguez-Hernandez, Gabriel Ceja-Espiritu, Xochitl G Briseño-Gomez, Hector R Galvan-Salazar, Alejandro D Soriano-Hernandez, Jose Guzman-Esquivel, Margarita L Martinez-Fierro, Oscar A Newton-Sanchez, Bertha A Olmedo Buenrostro, Iram P Rodriguez-Sanchez, Uriel A López-Lemus, Agustin Lara-Esqueda, Ivan Delgado-Enciso
Nonalcoholic steatohepatitis (NASH) is currently one of the primary liver diseases. Recent studies have shown a clinical relation between NASH and atherosclerosis. There is much interest in these two diseases because they are both associated with great morbidity and mortality. Inflammation and the overexpression of COX-2 participate in the pathophysiology of the two diseases, and therefore simultaneous treatment is feasible. The role of the four NSAIDs, meclofenamate, mefenamate, flufenamate, and aspirin, was analyzed in a mouse model of NASH, as well as preclinical atherosclerosis induced by a high-fat diet (HFD)...
2015: International Journal of Clinical and Experimental Medicine